Your fact-checks will appear here
Scientific article published on 01 January 2018
Neurocept’s investigational compound NE3107 has been evaluated in a Phase 2, open‑label study that reported , suggesting potential efficacy and a safety signal that supports further testing . Independ...
There is that a product named “Neurocept” improves memory in Alzheimer’s disease as of the sources provided; claims tying Neurocept to clinical benefit rest primarily on marketing materials and second...
The claim that Neurocept has advanced to Phase 3 trials for Alzheimer’s is not supported by the available analyses: none of the inspected sources document a clear Phase 3 registration or readout for a...
Dr. Sanjay Gupta’s public statements linking Neurocept (and related neurotherapies like NeuroEPO/NeuroAiD) to cognitive benefit rest on a mix of that some neuroactive compounds can affect brain health...